title: Prognostic significance of serum beta-2 microglobulin level in Hodgkin lymphoma treated with ABVD-based therapy.
abstract: The levels of serum beta-2 microglobulin (β2MG) are determined mainly from lymphoid tissue. To examine its prognostic value in Hodgkin lymphoma (HL), we conducted a retrospective analysis. We analyzed 67 patients with HL diagnosed and treated at seven institutes of the Yokohama City University Hematology Group between 1998 and 2011. The patients included 40 males and 27 females with a median age of 41 years (range 16-81 years). The HL subtypes were nodular sclerosis classical HL in 37 patients, mixed cellular classical HL in 23, lymphocyte-rich classical HL in 6, and nodular lymphocyte-predominant HL in 1. The 4-year overall survival (OS) rate of all 67 patients was 89 %. Patients with β2MG levels ≥ 2.5 mg/L (n = 18) showed inferior progression-free survival (PFS; 4-year PFS rate, 42 %) and inferior OS (4-year OS rate, 60 %) compared to patients who had β2MG levels <2.5 mg/L (n = 49; 4-year PFS rate, 87 %; 4-year OS rate, 98 %; P < 0.001). In multivariate analysis, only a serum β2MG level ≥ 2.5 mg/L was a significant adverse prognostic factor in regard to PFS (P = 0.04; relative risk 3.57). However, it was not significant prognostic factor for OS (P = 0.16) in the multivariate analysis. The serum β2MG level at diagnosis is a useful prognostic marker in patients with HL.
authors.affiliation: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan, yuki1234@yokohama-cu.ac.jp.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Nakajima
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Reina
authors.initials: R
authors.lastname: Watanabe
authors.forename: Yasufumi
authors.initials: Y
authors.lastname: Ishiyama
authors.forename: Eri
authors.initials: E
authors.lastname: Yamamoto
authors.forename: Daisuke
authors.initials: D
authors.lastname: Ishibashi
authors.forename: Megumi
authors.initials: M
authors.lastname: Itabashi
authors.forename: Satoshi
authors.initials: S
authors.lastname: Koyama
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Takahashi
authors.forename: Ayumi
authors.initials: A
authors.lastname: Numata
authors.forename: Hirotaka
authors.initials: H
authors.lastname: Takasaki
authors.forename: Rika
authors.initials: R
authors.lastname: Kawasaki
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Kuwabara
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Tanaka
authors.forename: Chizuko
authors.initials: C
authors.lastname: Hashimoto
authors.forename: Katsumichi
authors.initials: K
authors.lastname: Fujimaki
authors.forename: Rika
authors.initials: R
authors.lastname: Sakai
authors.forename: Shigeki
authors.initials: S
authors.lastname: Motomura
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D003606:Dacarbazine / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006689:Hodgkin Disease / Q000097:blood* / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012372:ROC Curve; D012189:Retrospective Studies; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use; D055815:Young Adult; D001613:beta 2-Microglobulin / Q000097:blood*
chemical_list: D000970:Antineoplastic Agents; D001613:beta 2-Microglobulin; D001761:Bleomycin; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin